These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 1575457

  • 1. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [Abstract] [Full Text] [Related]

  • 2. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS.
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [Abstract] [Full Text] [Related]

  • 3. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL.
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [Abstract] [Full Text] [Related]

  • 4. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [Abstract] [Full Text] [Related]

  • 5. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
    Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL.
    Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
    [Abstract] [Full Text] [Related]

  • 6. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study.
    Burn DJ, Rinne JO, Quinn NP, Lees AJ, Marsden CD, Brooks DJ.
    Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890
    [Abstract] [Full Text] [Related]

  • 7. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL.
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [Abstract] [Full Text] [Related]

  • 8. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH, Chung SJ, Kim JS, Lee MC.
    J Neurol Sci; 2006 May 15; 244(1-2):103-9. PubMed ID: 16473371
    [Abstract] [Full Text] [Related]

  • 9. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study.
    Brooks DJ, Ibanez V, Playford ED, Sawle GV, Leigh PN, Kocen RS, Harding AE, Marsden CD.
    Ann Neurol; 1991 Aug 15; 30(2):166-71. PubMed ID: 1897909
    [Abstract] [Full Text] [Related]

  • 10. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group.
    Ann Neurol; 2003 Jul 15; 54(1):93-101. PubMed ID: 12838524
    [Abstract] [Full Text] [Related]

  • 11. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, Moon DH, Oh SJ, Chung SJ, Lee CS.
    J Nucl Med; 2012 Mar 15; 53(3):399-406. PubMed ID: 22323779
    [Abstract] [Full Text] [Related]

  • 12. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I.
    J Neural Transm Suppl; 1997 Mar 15; 50():9-24. PubMed ID: 9120429
    [Abstract] [Full Text] [Related]

  • 13. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T.
    J Neurosurg; 2005 Dec 15; 103(6):968-73. PubMed ID: 16381182
    [Abstract] [Full Text] [Related]

  • 14. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.
    J Neurol Sci; 1995 Oct 15; 132(2):156-61. PubMed ID: 8543941
    [Abstract] [Full Text] [Related]

  • 15. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
    Turjanski N, Lees AJ, Brooks DJ.
    Neurology; 1997 Sep 15; 49(3):717-23. PubMed ID: 9305330
    [Abstract] [Full Text] [Related]

  • 16. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
    Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO.
    J Nucl Med; 2000 Jan 15; 41(1):65-70. PubMed ID: 10647606
    [Abstract] [Full Text] [Related]

  • 17. D2 receptor binding in dopa-responsive dystonia.
    Künig G, Leenders KL, Antonini A, Vontobel P, Weindl A, Meinck HM.
    Ann Neurol; 1998 Nov 15; 44(5):758-62. PubMed ID: 9818931
    [Abstract] [Full Text] [Related]

  • 18. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, Meucci N, Canesi M, Mariani C, Pezzoli G, Gerundini P.
    Neurol Sci; 2003 Oct 15; 24(3):149-50. PubMed ID: 14598060
    [Abstract] [Full Text] [Related]

  • 19. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.
    Ann Neurol; 1999 Nov 15; 46(5):723-31. PubMed ID: 10553989
    [Abstract] [Full Text] [Related]

  • 20. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease.
    Ilgin N, Zubieta J, Reich SG, Dannals RF, Ravert HT, Frost JJ.
    Neurology; 1999 Apr 12; 52(6):1221-6. PubMed ID: 10214747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.